A pilot study of QT interval analysis in overweight and obese youth

Published: Applied Nursing Research
Date:
Authors: Shirleatha Lee 1 , Patricia Ann Cowan, Pedro Velasquez-Mieyer
Abstract:
This descriptive pilot study examined if manual corrected QT (QTc) interval measures obtained from a standard 12-lead electrocardiogram (ECG) correlated with automated 24-hour ambulatory Holter QTc measures in 30 overweight and obese youth aged 12-17 years.

Prediabetes and blood pressure effects on heart rate variability, QT-interval duration, and left ventricular hypertrophy in overweight-obese adolescents

Published: The Journal of Pediatric Nursing
Date:
Authors: Shirleatha Lee 1 , Patricia Ann Cowan, Glenn T Wetzel, Pedro Velasquez-Mieyer
Abstract:
This ancillary, descriptive correlational study examined the effect of glucose regulation, blood pressure (BP), and their combined effects on cardiac autonomic function in 128 overweight-obese 11-18-year-olds.

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Published: The Lancet
Date:
Authors: Richard M Bergenstal 1, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter, DURATION-2 Study Group
Abstract:
Most patients with type 2 diabetes begin pharmacotherapy with metformin, but eventually need additional treatment. We assessed the safety and efficacy of once weekly exenatide, a glucagon-like peptide 1 receptor agonist, versus maximum approved doses of the dipeptidyl peptidase-4 inhibitor, sitagliptin, or the thiazolidinedione, pioglitazone, in patients treated with metformin.

Longitudinal study of muscle strength, quality, and adipose tissue infiltration

Published: Am J Clin Nutr
Date:
Authors: Matthew J Delmonico 1 , Tamara B Harris, Marjolein Visser, Seok Won Park, Molly B Conroy, Pedro Velasquez-Mieyer, Robert Boudreau, Todd M Manini, Michael Nevitt, Anne B Newman, Bret H Goodpaster, Health, Aging, and Body
Abstract:
Sarcopenia is thought to be accompanied by increased muscle fat infiltration. However, no longitudinal studies have examined concomitant changes in muscle mass, strength, or fat infiltration in older adults.

The prevalence of impaired glucose metabolism in Hispanics with two or more risk factors for metabolic syndrome in the primary care setting

Published: Journal of the American Academy of Nurse Practitioners
Date:
Authors: Claudia P Neira 1 , Margaret Hartig, Patricia A Cowan, Pedro A Velasquez-Mieyer
Abstract:
LINK TO RESEARCH https://pubmed.ncbi.nlm.nih.gov/19302694/ ABSTRACT Purpose: The purposes of this observational prospective study were (a) to identify the prevalence of undiagnosed impaired glucose metabolism (IGM) including impaired fasting glucose (IFG),...

Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus

Published: Expert Opin Pharmacother
Date:
Authors: Pedro A Velásquez-Mieyer 1 , Claudia P Neira
Abstract:
Type 1 diabetes mellitus is associated with acute and long-term complications, to which pre- and postprandial hyperglycemia are independent contributors. The objective of this review was to evaluate evidence-based information using biphasic insulin aspart 30 in the treatment of type 1 diabetes mellitus.

Racial disparity in glucagon-like peptide 1 and inflammation markers among severely obese adolescents

Published: Diabetes Care
Date:
Authors: Pedro A Velásquez-Mieyer 1 , Patricia A Cowan, Sylvia Pérez-Faustinelli, Ramfis Nieto-Martínez, Cesar Villegas-Barreto, Elizabeth A Tolley, Robert H Lustig, Bruce S Alpert
Abstract:
Compared with Caucasians, obese African-American adolescents have a higher risk for type 2 diabetes. Subclinical inflammation and reduced glucagon-like peptide 1 (GLP-1) concentration are linked to the pathogenesis of the disease.

Metabolic syndrome: from global epidemiology to individualized medicine

Published: Clinical Pharmacology & Therapeutics
Date:
Authors: J A Batsis 1 , R E Nieto-Martinez, F Lopez-Jimenez
Abstract:
The metabolic syndrome (MetS) encompasses a constellation of metabolic abnormalities that are thought to place patients at higher risk for the development of diabetes and cardiovascular (CV) disease.